CD34 and leukemia: Broadly expressed on AML LSCs in both CD34+ and CD34− disease; xenograft studies confirm leukemia-initiating capacity. Absent on HSCs, but present on normal monocytes and granulocytes. Ongoing development of CAR-T cells and antibody-drug conjugates to target CLL-1